
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $66M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Testosterone | Phase 2 | Hypoactive Sexual Desire Disorder |
| Sildenafil | Phase 2 | Hypoactive Sexual Desire Disorder |
| INS-GSH | Phase 2 | Parkinson Disease |
| 0.5 mgTestosterone + 10 mg Buspirone | Phase 2 | Hypoactive Sexual Desire Disorder |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.